Skip to main content
INTS
NASDAQ Life Sciences

Intensity Therapeutics Discloses $11.9M Preliminary Cash Balance, Zero Debt

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$7.69
Mkt Cap
$19.511M
52W Low
$4.633
52W High
$62.49
52W Position info
66% above low
Off High info
88% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

INTS sits 66% above its 52-week low of $4.633 on light trading volume (0.2× avg).

Summary

Intensity Therapeutics disclosed preliminary unaudited financial highlights as of December 31, 2025, reporting $11.9 million in cash and cash equivalents with no debt, providing a strong liquidity position for the micro-cap biotech.


Key Events · Financing and Capital Events · INTS

  • Strong Cash Position Reported

    The company reported preliminary, unaudited cash and cash equivalents of $11.9 million as of December 31, 2025.

  • Zero Debt and Low Liabilities

    Intensity Therapeutics highlighted a balance sheet with no reported debt and total liabilities of $1.4 million.

  • Capitalization Table Updated Post-Split

    The filing included an updated capitalization table, reflecting 2.52 million shares outstanding, restated for a 1-for-25 reverse stock split on February 19, 2026.


Analysis · INTS · Life Sciences

Intensity Therapeutics, a micro-cap life sciences company, reported preliminary unaudited financial highlights for Q4 2025, revealing a strong cash and cash equivalents balance of $11.9 million with no outstanding debt. This significant liquidity position provides a crucial financial runway for its operations and clinical development. While the figures are preliminary and subject to audit, they offer a positive indication of the company's financial health. The filing also included an updated capitalization table, adjusted for the 1-for-25 reverse stock split enacted on February 19, 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INTS was trading at $7.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.5M. The 52-week trading range was $4.63 to $62.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INTS - Latest Insights

INTS
Nov 05, 2026, 7:45 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.25
Real-time Price: $3.00 info
Change: -$0.250 (-8%) info
Market Cap: $8.814M info
INTS
Nov 05, 2026, 7:39 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.25
Real-time Price: $3.00 info
Change: -$0.250 (-8%) info
Market Cap: $8.814M info
INTS
Aug 11, 2026, 7:30 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $4.19
Real-time Price: $3.00 info
Change: -$1.19 (-28%) info
Market Cap: $8.814M info
INTS
Aug 11, 2026, 7:17 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.19
Real-time Price: $3.00 info
Change: -$1.19 (-28%) info
Market Cap: $8.814M info
INTS
Jun 16, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.71
Real-time Price: $3.00 info
Change: -$0.710 (-19%) info
Market Cap: $8.814M info